Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits Now Available Nationwide at Walgreens and Through On-Demand Delivery
June 08 2021 - 4:35PM
Business Wire
Kit Available Without a Prescription in Stores
and Delivered by DoorDash® and Instacart®
Labcorp (NYSE: LH), a leading global life sciences company today
announced that Pixel by Labcorp® COVID-19 PCR Test Home Collection
Kits are now in 6,000 Walgreens stores nationwide and through
Walgreens collaborations with on-demand delivery services DoorDash
and Instacart. The newly expanded availability and delivery option
advances Walgreens and Labcorp’s efforts to increase COVID-19
testing access in communities across the U.S., especially in
underserved areas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210608006093/en/
Photo courtesy of Labcorp
“Labcorp’s continued collaboration with Walgreens to make the
Pixel by Labcorp COVID-19 PCR Test Home Collection Kit more broadly
available helps us support our communities in returning to the
activities of our daily lives,” said Brian Caveney, M.D., chief
medical officer and president of Labcorp Diagnostics. “The
on-demand delivery option is especially useful for individuals who
might show symptoms of COVID-19 infection and want to be tested
without potentially infecting others. It would also be helpful for
people who may not have the flexibility to leave their home but
need access to testing.”
Customers will be able to purchase the Pixel by Labcorp COVID-19
PCR Test Home Collection Kit at the pharmacy counter without a
prescription, or they can order it for delivery through DoorDash
and Instacart. Additionally, the Pixel by Labcorp COVID-19 PCR Test
Home Collection Kit is available on Pixel by Labcorp and Walgreens
Find Care®, a digital health platform available on the Walgreens
app and at Walgreens.com. The expanded availability of the
collection kit will increase customers’ access to testing solutions
when and how they need them—at home, in stores, or in-person at one
of Walgreens conveniently located testing sites. As recently
announced, parents and guardians can request the kits for use with
children and adolescents ages 2-17 through the Pixel by Labcorp
website.
Customers can self-administer the test collection using a nasal
swab and send the sample back to Labcorp via prepaid FedEx Express
overnight shipping. Test results will then be available via the
Pixel by Labcorp website. If a COVID-19 test is positive, a
Labcorp-verified health care staff member will contact the
individual to discuss next steps. Pixel by Labcorp has contracted
with a physician network to make independent physician services
available for consultation.
The Pixel by Labcorp COVID-19 PCR Test Home Collection Kit has
not been FDA-cleared or approved, but has been authorized for
emergency use by the FDA under an EUA, and has been authorized only
for the detection of nucleic acid from SARS-CoV-2, not for any
other viruses or pathogens. Emergency use of this product is only
authorized for the duration of the declaration that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner. In-store availability is limited
and may vary by location.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
70,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn
more about us at http://www.Labcorp.com or follow us on LinkedIn
and Twitter @Labcorp.
Labcorp Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to clinical
laboratory testing and the potential benefits of a COVID-19 test
home collection kit and our responses to and the expected future
impacts of the COVID-19 pandemic and the opportunities for future
growth.
Each of the forward-looking statements is subject to change
based on various important factors, many of which are beyond the
Company’s control, including without limitation, whether our
response to the COVID-19 pandemic will prove effective, the impact
of the COVID-19 pandemic on our business and financial condition,
as well as on general economic, business, and market conditions,
competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers, the
Company’s satisfaction of regulatory and other requirements,
patient safety issues, changes in testing guidelines or
recommendations, federal, state, and local governmental responses
to the COVID-19 pandemic, adverse results in material litigation
matters, failure to maintain or develop customer relationships, our
ability to develop or acquire new products and adapt to
technological changes, failure in information technology, systems
or data security, and employee relations. These factors, in some
cases, have affected and in the future (together with other
factors) could affect the Company’s ability to implement the
Company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
The Company has no obligation to provide any updates to these
forward-looking statements even if our expectations change. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Further information on
potential factors, risks and uncertainties that could affect
operating and financial results is included in the Company’s most
recent Annual Report on Form 10-K and subsequent Forms 10-Q,
including in each case under the heading RISK FACTORS, and in the
Company’s other filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608006093/en/
Labcorp Contacts: Media: Christopher Allman-Bradshaw –
336-436-8263 Media@Labcorp.com Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com Walgreens Contact: Emily Mekstan
Media@walgreens.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024